Desmosterol (Normalized) Test

Your total cholesterol number tells you how much cholesterol is circulating in your blood, but it says nothing about where it came from. Is your body manufacturing too much? Is your gut absorbing too much from food? That distinction matters, because the best strategy for lowering cholesterol depends on the source.

Normalized desmosterol answers the manufacturing side of that question. Desmosterol sits one chemical step before cholesterol on the production line your cells use to build it. When your body ramps up cholesterol production, more desmosterol appears in your blood. Dividing that level by your total cholesterol creates a ratio that cancels out individual differences in overall cholesterol and isolates the production signal itself.

What This Ratio Reveals

Your body gets cholesterol from two sources: it makes cholesterol internally (synthesis), or it absorbs cholesterol from food through the gut. Most people lean toward one side or the other. Researchers have found that people can be broadly classified as "cholesterol synthesizers" or "cholesterol absorbers," and the pattern matters for disease risk and treatment choice.

Desmosterol is converted into cholesterol by an enzyme called DHCR24, the final step in one of the two main cholesterol-building pathways (known as the Bloch pathway). When synthesis is high, extra desmosterol circulates in your blood inside the same lipoprotein particles (the protein-fat packages that shuttle cholesterol through the bloodstream) that carry cholesterol. A foundational study of 63 healthy men confirmed that serum levels of cholesterol precursor sterols, including desmosterol, reliably track the rate of cholesterol synthesis measured by more complex methods.

In a clinical database of 667,718 patients, absolute desmosterol correlated very strongly with the desmosterol-to-cholesterol ratio (a statistical correlation of 0.94, where 1.0 would be a perfect match). This means the ratio is a stable, reliable way to measure synthesis activity across large and diverse populations. The same database showed that these sterol levels shift meaningfully with age and sex, with men generally showing higher synthesis activity than women.

Fatty Liver Disease

One of the strongest and most consistent findings in the desmosterol research links elevated levels to fatty liver disease and its more dangerous progression. Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly called non-alcoholic fatty liver disease) affects roughly one in four adults worldwide, and its inflammatory stage, called MASH (formerly NASH), is what drives liver scarring and failure.

In a study of 827 adults, serum desmosterol was significantly higher in those with biopsy-confirmed MASH compared to those with simple fat accumulation in the liver. The desmosterol-to-cholesterol ratio tracked with the amount of fat buildup, the level of inflammation, and the stage of scarring, suggesting that the liver's cholesterol production machinery shifts into overdrive as the disease worsens.

A 2025 study of 86 patients used a sterol and lipid signature including desmosterol to accurately distinguish MASH from milder MASLD without requiring a liver biopsy. Separately, a study of 167 adults with MASLD confirmed increased cholesterol production by the body and an impaired balance between synthesis and absorption, with desmosterol ratios reflecting that imbalance. In a study of 217 Japanese patients with biopsy-proven MASLD, desmosterol emerged as an independent predictor of liver inflammation, with roughly 3.7 times the odds of higher inflammation grade per unit increase, even after adjusting for liver enzymes and metabolic factors.

If your normalized desmosterol is elevated, fatty liver disease is one of the first things worth investigating, especially if you also have elevated liver enzymes (ALT, AST, or GGT), high triglycerides, or signs of insulin resistance.

Heart Disease Risk

The relationship between desmosterol and heart disease is real but less straightforward than the liver connection. In the Framingham Offspring Study, a well-known long-running heart health study of 569 adults, people who developed coronary heart disease actually had lower cholesterol synthesis markers and higher absorption markers compared to those who stayed healthy. In other words, the heart disease group leaned toward the "absorber" profile, not the "synthesizer" profile.

This seems to contradict the liver findings, where higher synthesis is the problem. But the apparent paradox resolves when you stop thinking of desmosterol as simply "good" or "bad" and instead see it as a clue to your metabolic pattern. Your synthesis-to-absorption balance tells you which metabolic pattern you fall into, and different patterns carry different risks for different diseases. High synthesizers face greater fatty liver and metabolic risk. High absorbers face greater cardiovascular risk. Both patterns can be harmful, just through different pathways.

A study of 100 healthy middle-aged adults found that higher desmosterol ratios, especially in men, were associated with more harmful cholesterol-carrying particle patterns and higher estimated cardiovascular risk scores. And research on 344 participants in a Brazilian cohort linked cholesterol synthesis and absorption markers to coronary artery calcium scores, a direct measure of plaque buildup. Elevated desmosterol in combination with high absorption markers may signal an especially unfavorable metabolic profile.

The practical takeaway: your normalized desmosterol result is most informative when read alongside absorption markers like campesterol and beta-sitosterol, not in isolation. The full synthesis-to-absorption picture is what predicts risk.

Alzheimer's Disease

One of the more striking findings in this field comes from the brain. In a study of 109 adults, plasma desmosterol was significantly decreased in people with Alzheimer's disease compared to age-matched controls, and the desmosterol-to-cholesterol ratio followed the same pattern. Using a measure of diagnostic accuracy called AUC (where 1.0 is perfect and 0.5 is no better than a coin flip), plasma desmosterol scored 0.80 for distinguishing Alzheimer's from controls. That is considered good discrimination.

The reduction was also present in people with mild cognitive impairment (MCI), the stage that often precedes full Alzheimer's. Desmosterol levels correlated with scores on the Mini-Mental State Examination, a standard cognitive test, meaning lower levels tracked with worse cognitive function. Separate research on brain tissue from Alzheimer's patients confirmed that the proportion of desmosterol in the brain itself is reduced compared to age-matched controls.

This remains a research finding, not a validated clinical screening tool for dementia. But it suggests that desmosterol may eventually become part of a panel for early cognitive risk assessment, particularly for people with a family history of Alzheimer's who want to track brain-related biomarkers over time.

Depression

In one of the largest population-based studies on this biomarker, involving 3,117 adults, plasma desmosterol levels were significantly associated with the severity of depressive symptoms. Lower desmosterol tracked with greater depression burden. The finding is cross-sectional, meaning it shows a snapshot association rather than proving that low desmosterol causes depression, but it adds to the emerging picture that cholesterol synthesis activity in the brain and body may influence mood and mental health.

Reference Ranges

No medical guidelines currently define standardized clinical cutpoints for normalized desmosterol. The values below come from research studies and represent population distributions, not treatment targets. Your lab may use different units or assay methods, so always compare your results within the same lab over time rather than against published numbers from a different source.

The largest available reference data comes from a clinical database of 667,718 patients measured by gas chromatography (a lab technique that separates and measures individual molecules in a blood sample). For absolute (non-normalized) desmosterol, the population mean was 0.99 µg/mL and the 99th percentile was 2.83 µg/mL. Values above the 99th percentile can support the diagnosis of extremely rare genetic conditions like desmosterolosis, where desmosterol accumulates because the enzyme that converts it to cholesterol is defective.

For the normalized ratio (desmosterol divided by total cholesterol), specific population-derived tiers have not been published in a format suitable for clinical cutpoints. This is an area where the science is still developing. What you can do right now is establish your own baseline and track your trend. A rising ratio over successive tests suggests your body's cholesterol production is increasing, which may warrant further investigation for fatty liver disease or metabolic changes. A declining ratio alongside cognitive symptoms could prompt a conversation with a neurologist.

Sex matters for interpretation. Research consistently shows that men tend to have higher cholesterol synthesis markers than women, while women tend to have higher absorption markers. Any reference range you encounter should ideally be sex-specific.

When Results Can Be Misleading

Cholesterol synthesis follows a daily rhythm, with production peaking during nighttime hours. A systematic review confirmed that synthesis markers, including desmosterol, show measurable variation depending on the time of day. For the most consistent results, draw your blood at approximately the same time for each test, ideally in the morning.

Acute illness can temporarily suppress cholesterol synthesis. In a controlled experiment, an injection of bacterial toxin (used to mimic acute inflammation) caused cholesterol-standardized desmosterol to drop within hours in healthy young men. If you have been sick with an infection, recovering from surgery, or dealing with any acute inflammatory condition, your desmosterol result may be falsely low. Wait at least two to three weeks after recovery before testing.

• Statin therapy: Statins reduce cholesterol synthesis and will lower your desmosterol. If you are taking a statin, your result reflects the drug's effect on your metabolism, not your natural baseline. This is clinically meaningful (the statin is working), but you should know your pre-statin level for comparison.
• Amiodarone: This heart rhythm medication has been observed to raise serum desmosterol in cardiac patients by blocking the enzyme (DHCR24) that converts desmosterol to cholesterol. The elevation does not mean your cholesterol synthesis rate has increased. It means the final conversion step is partially blocked. If you take amiodarone, your result will likely be elevated and should be interpreted with that context.
• Hepatitis C infection: Certain strains of hepatitis C (particularly genotype 3) disrupt cholesterol metabolism and can shift sterol profiles independently of your underlying metabolic health.

Tracking Your Trend

A single normalized desmosterol result tells you where you stand at one moment. That is useful as a baseline, but the real value emerges when you track the number over time. Cholesterol metabolism is dynamic. It shifts with your weight, your diet, your medications, and your metabolic health. Watching the trend lets you spot changes before they cross any threshold.

If you are making lifestyle changes, such as starting an exercise program or adjusting your diet, retest in three to six months to see whether your synthesis pattern has shifted. If your results are stable, annual testing is reasonable. If you are on a statin or another cholesterol-lowering therapy, testing before and after starting the medication gives you a clear picture of how your specific metabolism responds.

Because no universal clinical cutpoints exist for this ratio, your personal trend is the most reliable guide. A ratio that is climbing steadily deserves attention even if the absolute number is not flagged as "high" by any published range. A stable or declining ratio in someone managing metabolic risk is reassuring. Always compare results from the same lab using the same assay method. Different labs may produce different numbers for the same sample.

What To Do With Your Result

If your normalized desmosterol is elevated, the first priority is context. Check your liver enzymes (ALT, AST, GGT), triglycerides, and insulin resistance markers (fasting insulin, HOMA-IR). An elevated desmosterol alongside abnormal liver enzymes and high triglycerides strongly suggests fatty liver disease. A liver ultrasound or imaging study is a reasonable next step. If MASLD or MASH is suspected, a hepatologist or gastroenterologist can guide further evaluation.

Look at your companion sterol markers. Campesterol and beta-sitosterol reflect cholesterol absorption. If your desmosterol is high (synthesis up) while your absorption markers are low, you fit the "synthesizer" pattern, which responds well to statin therapy. If both are elevated, the picture is more complex and may point toward familial combined hyperlipidemia, which sometimes requires combination therapy.

If your normalized desmosterol is unexpectedly low, consider whether you are taking any medications that suppress cholesterol synthesis, especially statins. If not, and particularly if you are experiencing cognitive changes, the result may warrant further cognitive assessment alongside other brain health markers. Low desmosterol in the context of cognitive complaints is worth discussing with a neurologist.

For most people ordering this test proactively, the result is most powerful as part of the full sterols panel. The synthesis-to-absorption balance, not any single marker, is what drives clinical decisions. Establish your baseline, pair it with a standard lipid panel, and retest to track your trajectory.